Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 649-656

  Huang, Xiao Jun ^a   Xu, Lan Ping ^a   Liu, Kai Yan ^a   Liu, Dai Hong ^a   Chen, Huan ^a   Liu, Yan Rong ^a   Chen, Yu Hong ^a   Han, Wei ^a   Wang, Yu ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

BCR ABL; Blood and marrow transplantation; Chronic myeloid leukemia; HLA matched

Indexed keywords

ALPHA INTERFERON; BASILIXIMAB; BCR ABL PROTEIN; CYCLOSPORIN A; HYDROXYUREA; IMATINIB; MESSENGER RNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; BUSULFAN; CHILD; CYCLOPHOSPHAMIDE; FEMALE; FUSION PROTEINS, BCR-ABL; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RISK; RNA, MESSENGER; SIBLINGS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79954571026     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.023     Document Type: Article

References (25)

1. Zach O., Krieger O., Foedermayr M., Zellhofer B., Lutz D. OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. Leuk Lymphoma 2008, 49:2222-2223.
2. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91:513-521.
3. Weisser M., Ledderose G., Jochem Kolb H. Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade. Ann Hematol 2007, 86:127-132.
4. Radich J.P., Gooley T., Bensinger W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003, 102:31-35.
5. Crawley C., Szydlo R., Lalancette M., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005, 106:2969-2976.
6. Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95:67-71.
7. Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103:1548-1556.
8. Huang X.J., Liu D.H., Liu K.Y., Xu L.P., Chen H., Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007, 92:414-417.
9. Huang X.J., Wang Y., Liu D.H., et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study. J Clin Immunol 2008, 28:390-397.
10. Press R.D., Love Z., Tronnes A.A., et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006, 107:4250-4256.
11. Olavarria E., Kanfer E., Szydlo R., et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
12. Asnafi V., Rubio M.T., Delabesse E., et al. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2006, 20:793-799.
13. Xu L.P., Liu K.Y., Huang X.J., et al. The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse. Chin J Hematol 2008, 29:522-525.
14. Qin Y.Z., Li J.L., Zhu H.H., et al. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2006, 27. 511-414.
15. Qin Y., Jiang B., Jiang Q., et al. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Ann Hematol 2009, 88:37-41.
16. Qin Y.Z., Liu Y.R., Zhu H.H., et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008, 30:317-323.
17. Kantarjian H.M., Smith T.L., O'Brien S., Beran M., Pierce S., Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995, 122:254-261.
18. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
19. Jiang Q., Chen S.S., Jiang B., Jiang H., Lu Y., Lu D.P. [Efficacy and safety evaluation of imatinib in the treatment of patients with chronic granulocytic leukemia in accelerated phase]. Zhonghua Xue Ye Xue Za Zhi 2004, 25:333-336.
20. Weisser M., Tischer J., Schnittger S., Schoch C., Ledderose G., Kolb H.J. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006, 91:663-666.
21. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
22. International Bone Marrow trans Registry Available at:. http://http//www:bmtrory.
23. Lange T., Deininger M., Brand R., et al. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia 2004, 18:1468-1475.
24. Michallet A.S., Nicolini F., Furst S., et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 2005, 35:601-608.
25. Olavarria E., Siddique S., Griffiths M.J., et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007, 110. 4614-4517.